GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual meeting. Subscribe to ...

The obesity and diabetes markets are on the cusp of transformation, driven by cutting-edge GLP-1 therapies. Eli Lilly and Novo Nordisk are shaping the competitive landscape, with novel drugs like ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. There have been many headlines in the last week about $50 weight-loss drugs for Medicare ...

Taking weight-loss drugs means eating less—and for many Americans, dining out less, too. A growing body of research shows that people on GLP-1s are denting the restaurant business by cutting back on ...

The weight-loss drug rivalry heats up as another GLP-1 pill gains FDA approval This week the U.S. Food and Drug Administration approved a second GLP-1 pill for weight loss. The drug, called Foundayo, ...

Chanel Robinson achieved exactly what the gold rush of blockbuster weight-loss drugs promised: She lost nearly 100 pounds, lowered her cholesterol to normal levels and reined in her polycystic ovary ...

Some patients taking GLP-1 drugs to lose weight or manage Type 2 diabetes are discovering an emerging potential side effect from the blockbuster class of medications: the loss of pleasure or an ...

Side effects like nausea, vomiting, diarrhea and constipation are common soon after starting GLP-1s or increasing the drug’s dosage. A nutrient-dense diet and regular exercise are essential when on a ...

Stevee Williams, a restaurant manager in Houston, was preparing for her sister’s wedding when anxieties bubbled up about how she would look in her bridesmaid dress. She was diagnosed with anorexia ...

A huge international review found that GLP-1 weight-loss drugs significantly reduce the risk of heart attacks, strokes, heart failure, and premature death over the long term. Researchers say these ...

Share on Pinterest The FDA puts forward a move to exclude GLP-1 drugs from the bulk compounding list. Image credit: VICTOR TORRES/Stocksy On April 30, 2026, the U.S. FDA announced it is considering ...

After capturing the North American market with Wegovy (semaglutide) and Zepbound (tirzepatide), Novo Nordisk A/S and Eli Lilly and Co. are advancing blockbuster glucagon-like peptide-1 (GLP-1) ...